114 related articles for article (PubMed ID: 12150448)
1. Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients.
Schiffman K; Rinn K; Disis ML
Breast Cancer Res Treat; 2002 Jul; 74(1):17-23. PubMed ID: 12150448
[TBL] [Abstract][Full Text] [Related]
2. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
Disis ML; Schiffman K; Gooley TA; McNeel DG; Rinn K; Knutson KL
Clin Cancer Res; 2000 Apr; 6(4):1347-50. PubMed ID: 10778962
[TBL] [Abstract][Full Text] [Related]
3. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
Morse MA; Hobeika A; Osada T; Niedzwiecki D; Marcom PK; Blackwell KL; Anders C; Devi GR; Lyerly HK; Clay TM
J Transl Med; 2007 Sep; 5():42. PubMed ID: 17822557
[TBL] [Abstract][Full Text] [Related]
4. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
Valdez H; Smith KY; Landay A; Connick E; Kuritzkes DR; Kessler H; Fox L; Spritzler J; Roe J; Lederman MB; Lederman HM; Evans TG; Heath-Chiozzi M; Lederman MM
AIDS; 2000 Jan; 14(1):11-21. PubMed ID: 10714563
[TBL] [Abstract][Full Text] [Related]
5. The use of tetanus toxoid to elucidate the delayed-type hypersensitivity response in an older, immunized population.
French AL; McCullough ME; Rice KT; Schultz ME; Gordin FM
Gerontology; 1998; 44(1):56-60. PubMed ID: 9436017
[TBL] [Abstract][Full Text] [Related]
6. Three suitable antigens for delayed-type hypersensitivity skin testing in a tropical country like Thailand.
Siripassorn K; Charoenwongse P; Ruxrungtham K
Asian Pac J Allergy Immunol; 2006; 24(2-3):143-52. PubMed ID: 17136880
[TBL] [Abstract][Full Text] [Related]
7. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.
Disis ML; Knutson KL; Schiffman K; Rinn K; McNeel DG
Breast Cancer Res Treat; 2000 Aug; 62(3):245-52. PubMed ID: 11072789
[TBL] [Abstract][Full Text] [Related]
8. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
9. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
10. Delayed-type hypersensitivity skin testing in human immunodeficiency virus-infected pediatric patients.
Raszka WV; Moriarty RA; Ottolini MG; Waecker NJ; Ascher DP; Cieslak TJ; Fischer GW; Robb ML
J Pediatr; 1996 Aug; 129(2):245-50. PubMed ID: 8765622
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
12. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
13. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
Habal N; Gupta RK; Bilchik AJ; Yee R; Leopoldo Z; Ye W; Elashoff RM; Morton DL
Ann Surg Oncol; 2001 Jun; 8(5):389-401. PubMed ID: 11407512
[TBL] [Abstract][Full Text] [Related]
14. In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.
Rodriguez B; Valdez H; Lange CG; Asaad R; Medvik K; Sieg SF
Clin Immunol; 2010 Sep; 136(3):400-8. PubMed ID: 20472504
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous delayed-type hypersensitivity responsiveness in lepromatous and borderline lepromatous leprosy patients as determined by MULTITEST CMI.
Walsh DS; Villahermosa LG; Balagon MV; Abalos RM; Fajardo TT; Tan EV; Cellona RV; Walsh GP
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):518-26. PubMed ID: 10774662
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two methods for the assessment of delayed-type hypersensitivity skin responses in patients with human immunodeficiency virus infection.
Martínez-Marcos FJ; López-Cortés LF; Pachón J; Alarcón A; Cordero E; Viciana P
Clin Infect Dis; 1998 Jun; 26(6):1330-4. PubMed ID: 9636858
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated immunity assessed by Multitest CMI skin testing in infants and preschool children.
Kniker WT; Lesourd BM; McBryde JL; Corriel RN
Am J Dis Child; 1985 Aug; 139(8):840-5. PubMed ID: 4025264
[TBL] [Abstract][Full Text] [Related]
18. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
19. Tetanus toxoid as an antigen for delayed cutaneous hypersensitivity.
Delafuente JC; Eisenberg JD; Hoelzer DR; Slavin RG
JAMA; 1983 Jun; 249(23):3209-11. PubMed ID: 6343648
[TBL] [Abstract][Full Text] [Related]
20. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
